Atlan Pharma

Atlan Pharma is a French biotechnology company specializing in the development of targeted therapies for bone-related diseases and oncology. Based in Nantes, the company utilizes a proprietary bone-targeting platform that conjugates therapeutic agents to bisphosphonate-like molecules, which have a high affinity for hydroxyapatite in bone tissue. This approach aims to increase the local concentration of drugs in the bone while reducing systemic toxicity. Their lead programs focus on treating bone metastases and primary bone tumors like osteosarcoma. The company is a spin-off from the University of Nantes and the CNRS, leveraging decades of expertise in calcium phosphate chemistry and bone biology.